Effects of the Luteinizing Hormone-Releasing Hormone Agonist Leuprolide on Lipoproteins, Fibrinogen and Plasminogen Activator Inhibitor in Patients with Benign Prostatic Hyperplasia

Eri, Lars M.; Urdal, Petter; Bechensteen, A. G.

doi:10.1097/00005392-199507000-00035

Cited by 20 publications

(25 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 GnRH agonists also increase serum triglycerides and low density lipoprotein cholesterol. 5,8,10 Consistent with these adverse metabolic effects, GnRH agonists are associated with greater risk of incident diabetes mellitus and cardiovascular disease in men with prostate cancer. 11…”

Section: Introductionmentioning

confidence: 97%

Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer

Smith¹,

Lee²,

Fallon³

et al. 2008

Urology

110

View full text Add to dashboard Cite

Objectives-Gonadotropin-releasing hormone agonists increase fat mass, decrease insulin sensitivity, and increase serum triglycerides-changes suggestive of the classic metabolic syndrome. These analyses were designed to assess the effects of gonadotropin-releasing hormone agonist treatment on other markers of the metabolic syndrome including adiponectin, resistin, and plasminogen activator inhibitor type 1 (PAI-1) levels and to evaluate relationships between changes in adipocytokines, body composition, and insulin sensitivity.Methods-In this prospective 12-week study, 25 nondiabetic men with locally advanced or recurrent prostate cancer and no radiographic evidence of metastases were treated with leuprolide depot and bicalutamide. Outcomes included changes from baseline to week 12 in body composition, insulin sensitivity, and levels of adiponectin, resistin, and PAI-1.Results-Mean (± SE) percentage fat body mass increased by 4.3 ± 1.3% from baseline to week 12 (P=0.002). Insulin sensitivity index decreased by 12.9 ± 7.6% (P=0.02). Serum adiponectin levels increased by 37.4 ± 7.2% from baseline to week 12 (P<0.001). In contrast, serum resistin levels did not change significantly. Changes in adiponectin were associated with changes lean mass (r=0.448; P=0.02) and fat mass (r=−0.383; P=0.06) but not changes in insulin sensitivity.Conclusions-Combined androgen blockade with leuprolide and bicalutamide significantly increased serum adiponectin levels but did not alter PAI-1 or resistin levels. This pattern of metabolic changes appears distinct from the classic metabolic syndrome.

show abstract

Section: Introductionmentioning

confidence: 97%

Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer

Smith¹,

Lee²,

Fallon³

et al. 2008

Urology

110

View full text Add to dashboard Cite

show abstract

“…21 In their study, Eri et al evaluated the impact of the luteinizing hormone-releasing hormone (LHRH) agonist leuprolide on 26 patients with benign prostatic hyperplasia (BPH) and showed that the mean total cholesterol level increased by 10.6%, HDL cholesterol by 8.2%, and triglycerides by 26.9%, but LDL levels were unchanged. 27 Smith et al in their study on 26 men treated with leuprolide for 12 months showed the same increase in HDL levels. 28 In our study, the mean amount of trigycerides in patients significantly increased after both six and 12 months.…”

Section: Adt and Hyperlipidemiamentioning

confidence: 69%

Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy

Rezaei¹,

Rezaei²,

Ghoreifi

et al. 2016

CUAJ

View full text Add to dashboard Cite

Introduction: The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT. Methods: In this longitudinal study, we studied the prevalence of metabolic syndrome and its components in 190 patients who were undergoing intermittent ADT. The metabolic syndrome was defined according to the Adult Treatment Panel III criteria. All metabolic parameters, including lipid profile, blood glucose, blood pressures, and waist circumferences of the patients were measured six and 12 months after treatment. Results: Mean age of the patients was 67.5 ± 6.74 years. The incidence of metabolic syndrome after six and 12 months was 6.8% and 14.7%, respectively. Analysis of various components of the metabolic syndrome revealed that patients had significantly higher overall prevalence of hyperglycemia, abdominal obesity, and hypertriglyceridemia in their six-and 12-month followups, but blood pressure has not been changed in the same period except for diastolic blood pressure after six months. Conclusions: Although there was an increased risk of metabolic syndrome in patients receiving intermittent ADT, it was lower than other studies that treated the same patients with continuous ADT. Also it seems that intermittent ADT has less metabolic complications than continuous ADT and could be used as a safe alternative in patients with advanced and metastatic PCa.

show abstract

“…8,[25][26][27][28] ADT significantly increases fat mass, decreases lean body mass, 29,30 increases fasting plasma insulin and decreases insulin sensitivity 31 and increases serum cholesterol and triglyceride levels. 29,32,33 There are limitations in this current study. Firstly, the study was conducted in a single city in British Columbia.…”

Section: Wallis Et Almentioning

confidence: 91%

Testosterone deficiency syndrome and cardiovascular health: An assessment of beliefs, knowledge and practice of general practitioners and cardiologists in Victoria, BC

Wallis

Nelson²,

Pommerville³

2014

CUAJ

View full text Add to dashboard Cite

Introduction: Testosterone deficiency syndrome (TDS) has been shown to be an independent cardiovascular risk factor and a predisposing factor for metabolic syndrome. As general practitioners and cardiologists primarily care for these patients, we sought to assess their knowledge, beliefs and practice patterns with respect to TDS and cardiac health. Methods: We distributed a questionnaire to all 20 cardiologists and a cohort of 128 family practitioners in Victoria, British Columbia. Of the 13 questions, 10 assessed knowledge and beliefs on TDS and 3 assessed current practice patterns. Results: Most respondents believed that TDS is a medical condition (66.7%) and could negatively affect body composition (62%), but a similar majority was unsure whether it was a cardiac risk factor (66.7%). While most believed that testosterone replacement therapy (TRT) could improve exercise tolerance (62%), most were unsure if it was beneficial in cardiac patients. Cardiologists were significantly less likely to believe that TRT was beneficial in preventing recurrent myocardial infarction and improving myocardial perfusion (p = 0.0133, 0.00186, respectively). The vast majority (88%) did not screen cardiac patients for TDS. If a patient was identified as having TDS, only10% of those surveyed would refer these patients to a urologist. Conclusion: Despite its prevalence in cardiac patients, TDS is not well-understood by general practitioners and cardiologists; they lack knowledge on its deleterious cardiovascular effects. In their role as men's health advocates, urologists should educate our colleagues regarding the correlation between TDS and cardiovascular mortality and risk factors. Limitations of this study include small sample size and restricted geographic scope.

show abstract

Effects of the Luteinizing Hormone-Releasing Hormone Agonist Leuprolide on Lipoproteins, Fibrinogen and Plasminogen Activator Inhibitor in Patients with Benign Prostatic Hyperplasia

Cited by 20 publications

References 18 publications

Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer

Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer

Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy

Testosterone deficiency syndrome and cardiovascular health: An assessment of beliefs, knowledge and practice of general practitioners and cardiologists in Victoria, BC

Contact Info

Product

Resources

About